Torrent Pharmaceuticals eyes ₹5,000 cr QIP following JB Pharma buy
Revenue hit ₹4,197 crore on maiden JB Pharma consolidation; board recommends ₹9 dividend despite profit hit from acquisition costs.
— 2 earlier stories on Torrent Pharmaceuticals Ltd. →What's new with Torrent Pharmaceuticals Ltd.
- Board seeking shareholder approval for a ₹5,000 cr QIP.
- Q4 revenue rose 42% to ₹4,197 cr, with base business up 16%.
- Net profit of ₹364 cr tempered by acquisition costs and depreciation.
Why this matters for Torrent Pharmaceuticals Ltd.
The capital raise is the real news here. A ₹5,000 crore QIP for a company of this scale suggests management is prepping for further inorganic growth or a rapid deleveraging. While earnings growth looks good, the market now has to price in the equity dilution that comes with this much new capital.
What we're watching
- Specific timing and pricing of the proposed QIP.
- Margin trajectory as JB Pharma's integration costs normalize.
- Debt reduction versus further M&A activity.
The full read
Torrent Pharmaceuticals closed FY26 with a 42% revenue surge to ₹4,197 crore, marking its first full quarter of consolidated performance with the recently acquired JB Pharma. Branded business growth of 16% provided a clear organic tailwind, though net profit lagged at ₹364 crore as acquisition-related expenses and depreciation took their toll. The board recommended a final dividend of ₹9 per share, but the more vital signal is the move to raise ₹5,000 crore via a qualified institutional placement. The market largely expected these numbers from earlier intimations, leaving little immediate room for price discovery on the results themselves. The real test is the QIP. It is a large capital raise that shifts the focus from last year’s operational performance to the company’s next expansionary move. Shareholders now wait to see if this cash flows toward a cleaner balance sheet or another acquisition hunt.